Monitoring of Monoamine Oxidases as Biomarkers of Disease and Disorder

Kim, Dokyoung; Beck, Sungjun; Jung, Junyang

doi:10.1002/bkcs.11397

Cited by 4 publications

(7 citation statements)

References 19 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Meanwhile, the two-photon emission spectrum in the presence or absence of MAO-B was tested (Figure S1), and the two-photon absorption cross-sectional area was calculated to be 39.25. 26 All these data indicated that BiPhAA could quickly react with MAO-B and emit bright fluorescence.…”

Section: ■ Results and Discussionmentioning

confidence: 91%

“…Additionally, before and after the reaction, the fluorescence quantum yield (φ) was determined to be 0.048 and 0.113, respectively. Meanwhile, the two-photon emission spectrum in the presence or absence of MAO-B was tested (Figure S1), and the two-photon absorption cross-sectional area was calculated to be 39.25 . All these data indicated that BiPhAA could quickly react with MAO-B and emit bright fluorescence.…”

Section: Resultsmentioning

confidence: 94%

“…Monoamine oxidase (EC 1.4.3.4, MAO) is a flavinase-dependent enzyme that can catalyze and oxidate ammonia substrates to corresponding imines. , MAO includes two isozymic forms, MAO-A and MAO-B, that are widely distributed in tissues. In particular, the highest MAO level is in the liver. , A considerable number of studies show that serotonin (5-HT) is liable to be degraded by MAO-A, which is involved in maintaining the homeostasis of monoamine neurotransmitters in the biological system. , Meanwhile, MAO-B’s main catalytic substrates are benzylamine and phenethylamine, and it participates in the formation of collagen fibers. − Many researchers report that there is a high MAO-B level in the serum of early-stage liver fibrosis patients, and it is considered to be an ideal hallmark for liver fibrosis diagnosis. , So, the development of an appropriate strategy to monitor MAO-B in situ will boost the diagnosis of early-stage liver fibrosis and thorough understanding of the vital role of MAO-B during liver fibrosis.…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Rapid Two-Photon Fluorescence Imaging of Monoamine Oxidase B for Diagnosis of Early-Stage Liver Fibrosis in Mice

Fan

Zhou

et al. 2021

Anal. Chem.

View full text Add to dashboard Cite

Liver fibrosis could induce cirrhosis and liver cancer, causing serious damages to liver function and even death. Early diagnosis of fibrosis is extremely requisite for optimizing treatment schedule to improve cure rate. In early-stage fibrosis, overexpressed monoamine oxidase B (MAO-B) can serve as a biomarker, which greatly contributes to the diagnosis of early liver fibrosis. However, there is still a lack of desired strategy to precisely monitor MAO-B in situ. In this work, we established a two-photon fluorescence imaging method for in vivo detection of MAO-B activity counting on a simply prepared probe, BiPhAA. The BiPhAA could be activated by MAO-B within 10 min and fluoresced brightly. To our knowledge, this BiPhAA-based imaging platform for MAO-B is more rapid than other current detection methods. Furthermore, BiPhAA allowed the dynamic observation of endogenous MAO-B level changes in hepatic stellate cells (LX-2). Through two-photon fluorescence imaging, we observed six times higher fluorescence brightness in the liver tissue of fibrosis mice than that of normal mice, thus successfully distinguishing mice with liver fibrosis from normal mice. Our work offers a simple, fast, and highly sensitive approach for imaging MAO-B in situ and paves a way to the diagnosis of early liver fibrosis with accuracy.

show abstract

Section: ■ Results and Discussionmentioning

confidence: 91%

Section: Resultsmentioning

confidence: 94%

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Rapid Two-Photon Fluorescence Imaging of Monoamine Oxidase B for Diagnosis of Early-Stage Liver Fibrosis in Mice

Fan

Zhou

et al. 2021

Anal. Chem.

View full text Add to dashboard Cite

show abstract

“…Reports have shown that excessive levels of MAOs, especially MAO‐B, can be found in the AD brain. [ 122 ] The nonfluorescent probe 96 (Figure 11B; Section 2.1.3) generated a fluorescent dipolar dye, benzo[ g ]iminocoumarin 2 (IBC 2), by the enzymatic oxidation of MAO, which could be used to selectively detect Aβ plaques ( Figure A). It was found that the conversion speed of probe 96 to IBC 2 by the oxidation of MAO‐B ( k obs : 6.4 s −1 ) was a little faster than that of MAO‐A ( k obs : 5.8 s −1 ).…”

Section: Alzheimer's Diseasementioning

confidence: 99%

Fluorescent Diagnostic Probes in Neurodegenerative Diseases

et al. 2020

View full text Add to dashboard Cite

Both chronic and acute neurodegenerative diseases have been associated with high morbidity and mortality, along with the death of neurons in different areas of the brain, and there are few or no effective curative therapy options for treatment of patients. [3,4] These disorders are a major cause of concern for the health and quality of life in the aging society, since age is the greatest risk factor for neurodegenerative disease. [5] The World Health Organization has predicted that in next 20 years neurodegenerative disease will become the second most common cause of mortality after cardiovascular disease. [6] Neurodegenerative processes begin long before their clinical symptoms are evident, and evolve for years slowly and irreversibly. Hence, there is an urgent need to diagnose neurodegenerative disease as early as possible and to distinguish between different neurodegenerative disorders with shared and unique symptoms to facilitate decision making regarding choice of treatment. Timely diagnosis is important for the adoption of therapeutic modalities in clinical trials prior to moderate dementia exhibition, to appraise and apply antidotes to maximally preserve the cognitive functions or to slow down the course of these disorders. The ability to analyze and identify risk factors for cognitive deficit would represent an extraordinary advancement in the field of dementia. [5] The main modern diagnostic technologies for the early examination of neurodegenerative disease pathology, neuroimaging techniques, include radioligandsbased positron emission tomography (PET), 3D single-photon emission-computed tomography (SPECT), and structural magnetic resonance imaging (MRI). Although PET and SPECT are the most used imaging techniques for neurodegenerative diseases, their application is limited by high cost, involvement of hazardous radiolabeled compounds, need for sophisticated instruments, and application of complex data acquisition and analysis protocols. The MRI technique has relatively low spatial resolution as well as intrinsically poor sensitivity to distinguish morphological differences between disease biomarkers and the surrounding tissue. Recently, fluorescence diagnosis technology has become an attractive and potential alternative to diagnose and probe the progression of neurodegenerative diseases, because of being rapid, noninvasive, sensitive, simple, real-time, low-cost, and high-resolution in nature. [7] There are several uses for Neurodegenerative diseases are debilitating disorders that feature progressive and selective loss of function or structure of anatomically or physiologically associated neuronal systems. Both chronic and acute neurodegenerative diseases are associated with high morbidity and mortality along with the death of neurons in different areas of the brain; moreover, there are few or no effective curative therapy options for treating these disorders. There is an urgent need to diagnose neurodegenerative disease as early as possible, and to distinguish between different disorders with overlap...

show abstract

“…68−72 A high level of MAOs, particularly MAO-B, was observed in the AD brain. 73 In 2012, Ahn and co-workers used a two-photon MAO probe, which, upon enzymatic reaction, produces a fluorescent dye that can also sense Aβ plaques, to monitor a close correlation between the MAO-B activity and accumulation of Aβ plaques upon aging. A further study is necessary to understand the close correlation and also to know whether the enzyme activity is associated with the progress of AD.…”

Section: Upregulated Monoamine Oxidasesmentioning

confidence: 99%

Frontiers in Probing Alzheimer’s Disease Biomarkers with Fluorescent Small Molecules

et al. 2019

Self Cite

View full text Add to dashboard Cite

Alzheimer’s disease (AD) is the most common form of dementia. The pathogenesis of the disease is associated with aggregated amyloid-β, hyperphosphorylated tau, a high level of metal ions, abnormal enzyme activities, and reactive astrocytes. This outlook gives an overview of fluorescent small molecules targeting AD biomarkers for ex vivo and in vivo imaging. These chemical imaging probes are categorized based on the potential biomarkers, and their pros and cons are discussed. Guidelines for designing new sensing strategies as well as the desirable properties to be pursued for AD fluorescence imaging are also provided.

show abstract

Monitoring of Monoamine Oxidases as Biomarkers of Disease and Disorder

Cited by 4 publications

References 19 publications

Rapid Two-Photon Fluorescence Imaging of Monoamine Oxidase B for Diagnosis of Early-Stage Liver Fibrosis in Mice

Rapid Two-Photon Fluorescence Imaging of Monoamine Oxidase B for Diagnosis of Early-Stage Liver Fibrosis in Mice

Fluorescent Diagnostic Probes in Neurodegenerative Diseases

Frontiers in Probing Alzheimer’s Disease Biomarkers with Fluorescent Small Molecules

Contact Info

Product

Resources

About